We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
- Authors
Camilio, Ketil A.; Wang, Meng-Yu; Mauseth, Brynjar; Waagene, Stein; Kvalheim, Gunnar; Rekdal, Øystein; Sveinbjørnsson, Baldur; Mælandsmo, Gunhild M.
- Abstract
<bold>Background: </bold>Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable of reshaping the tumor microenvironment, turning "cold" tumors "hot" through a significant increase in tumor-infiltrating lymphocytes.<bold>Methods: </bold>We investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model. Tumor growth curves were compared using one-way ANOVA analysis of variance and Tukey's multiple comparisons test, and animal survival curves were compared using the log-rank (Mantel-Cox) test. We considered p values ≤0.05 to indicate statistical significance.<bold>Results: </bold>We found that LTX-315 displayed a strong additive antitumoral effect when used in combination with CAELYX®, and induced immune-mediated changes in the tumor microenvironment, followed by complete regression in the majority of animals treated. Furthermore, imaging techniques and histological examination showed that the combination induced strong local necrosis, followed by an increase in the infiltration of CD4+ and CD8+ immune cells into the tumor parenchymal tissue.<bold>Conclusions: </bold>Our data demonstrate that LTX-315 is a promising combination partner with CAELYX® for the treatment of triple-negative breast cancer.
- Subjects
TRIPLE-negative breast cancer; BREAST cancer; ANALYSIS of variance; CELL tumors; CELL death; ANIMAL experimentation; ANTINEOPLASTIC agents; BIOLOGICAL models; BREAST tumors; CELL lines; CELL physiology; COMPARATIVE studies; DOXORUBICIN; CLINICAL drug trials; LYMPHOCYTES; RESEARCH methodology; MEDICAL cooperation; MICE; OLIGOPEPTIDES; POLYETHYLENE glycol; RESEARCH; SURVIVAL analysis (Biometry); T cells; EVALUATION research; TREATMENT effectiveness; PHARMACODYNAMICS; THERAPEUTICS
- Publication
Breast Cancer Research, 2019, Vol 21, Issue 1, pN.PAG
- ISSN
1465-5411
- Publication type
journal article
- DOI
10.1186/s13058-018-1092-x